Lynch Receives Bristol-Myers Squibb Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

NEW YORK--Henry T. Lynch, MD, whose pioneering work during the 1960s and '70s helped establish the hereditary basis of certain gastrointestinal, breast, and ovarian cancers, is the recipient of the 19th annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research. Thanks in large part to Dr. Lynch, the specific genetic mutations responsible for a number of familial cancers have been identified.

NEW YORK--Henry T. Lynch, MD, whose pioneering work during the1960s and '70s helped establish the hereditary basis of certaingastrointestinal, breast, and ovarian cancers, is the recipientof the 19th annual Bristol-Myers Squibb Award for DistinguishedAchievement in Cancer Research. Thanks in large part to Dr. Lynch,the specific genetic mutations responsible for a number of familialcancers have been identified.

Dr. Lynch is professor of medicine and chairman of preventivemedicine and public health, Creighton University School of Medicine,Omaha.

Related Videos
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
Cell therapy and vaccine approaches are among the several potential options for targeting KRAS in patients with KRAS G12C–mutated non–small cell lung cancer, says Sandip P. Patel, MD.
Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, experts on colorectal cancer
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Related Content